Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non–Small-Cell Lung CancerAlona Zer, Natasha B. Leighl, Preet Walia et al.|Clinical Lung Cancer|2018Cited by 144
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous <i>EGFR</i> -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY TrialD. Ross Camidge, Shun Lü, Chih‐Hsi S. Kuo et al.|Journal of Clinical Oncology|2024Cited by 131
Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non–small cell lung cancer: A real-world multicentre studyAntoine Desîlets, Arielle Elkrief, Félix Blanc‐Durand et al.|European Journal of Cancer|2020Cited by 78
Association of Circulating Tumor DNA Testing Before Tissue Diagnosis With Time to Treatment Among Patients With Suspected Advanced Lung CancerMiguel García-Pardo, Natasha B. Leighl, Kasia Czarnecka‐Kujawa et al.|JAMA Network Open|2023Cited by 60
Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorsAlona Zer, Frances A. Shepherd, Keyue Ding et al.|Journal of Thoracic Oncology|2015Cited by 55